Study to Assess PK, Safety and Tolerability Early in Healthy Subjects - Trial NCT06388772
Access comprehensive clinical trial information for NCT06388772 through Pure Global AI's free database. This Phase 1 trial is sponsored by Changzhou Qianhong Bio-pharma Co., Ltd. and is currently Completed. The study focuses on Acute Ischemic Stroke. Target enrollment is 74 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Changzhou Qianhong Bio-pharma Co., Ltd.
Timeline & Enrollment
Phase 1
Jul 05, 2021
Jan 06, 2023
Primary Outcome
Safety as assessed by incidence, severity, and causality of adverse events,Plasma measurements of QHRD106
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of
 QHRD106 early in Chinese healthy subjects with single doses.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06388772
Non-Device Trial